Similar articles for PMID: 15794020

Year	Number of Results
1968	1
1976	1
1985	1
1988	1
1992	1
1994	1
1995	1
1999	2
2000	4
2002	2
2003	2
2004	9
2005	7
2006	2
2007	1
2009	3
2010	3
2011	2
2012	1
2013	4
2014	2
2015	4
2022	0

1

Hyperkalemia associated with spironolactone therapy.

Dolovich L, Gavura S, Pottie K. Dolovich L, et al. Can Fam Physician. 2005 Mar;51(3):357-60. Can Fam Physician. 2005. PMID: 15794020 Free PMC article. No abstract available.

2

Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.

Abbas S, Ihle P, Harder S, Schubert I. Abbas S, et al. Pharmacoepidemiol Drug Saf. 2015 Apr;24(4):406-13. doi: 10.1002/pds.3748. Epub 2015 Feb 12. Pharmacoepidemiol Drug Saf. 2015. PMID: 25683504

3

Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.

Fujii H, Nakahama H, Yoshihara F, Nakamura S, Inenaga T, Kawano Y. Fujii H, et al. Kobe J Med Sci. 2005;51(1-2):1-6. Kobe J Med Sci. 2005. PMID: 16199929 Free article.

4

Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne.

Plovanich M, Weng QY, Mostaghimi A. Plovanich M, et al. JAMA Dermatol. 2015 Sep;151(9):941-4. doi: 10.1001/jamadermatol.2015.34. JAMA Dermatol. 2015. PMID: 25796182

5

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Juurlink DN, et al. N Engl J Med. 2004 Aug 5;351(6):543-51. doi: 10.1056/NEJMoa040135. N Engl J Med. 2004. PMID: 15295047 Free article.

6

The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.

Shah KB, Rao K, Sawyer R, Gottlieb SS. Shah KB, et al. J Am Coll Cardiol. 2005 Sep 6;46(5):845-9. doi: 10.1016/j.jacc.2005.06.010. J Am Coll Cardiol. 2005. PMID: 16139135 Free article.

7

Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.

Abbas Z, Mumtaz K, Salam A, Jafri W. Abbas Z, et al. J Coll Physicians Surg Pak. 2003 Jul;13(7):382-4. J Coll Physicians Surg Pak. 2003. PMID: 12887837

8

Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.

Muzzarelli S, Maeder MT, Toggweiler S, Rickli H, Nietlispach F, Julius B, Burkard T, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF Investigators. Muzzarelli S, et al. Am J Cardiol. 2012 Mar 1;109(5):693-8. doi: 10.1016/j.amjcard.2011.10.027. Epub 2011 Dec 5. Am J Cardiol. 2012. PMID: 22152974 Clinical Trial.

9

Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.

Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators. Vardeny O, et al. Circ Heart Fail. 2014 Jul;7(4):573-9. doi: 10.1161/CIRCHEARTFAILURE.114.001104. Epub 2014 May 8. Circ Heart Fail. 2014. PMID: 24812304 Clinical Trial.

10

Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.

Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y. Saito M, et al. J Clin Pharm Ther. 2005 Dec;30(6):603-10. doi: 10.1111/j.1365-2710.2005.00694.x. J Clin Pharm Ther. 2005. PMID: 16336294 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed